381P - Clinical study of apatinib in the treatment of malignant pleural effusion and malignant celiac effusion

Abstract

Background: Malignant pleural effusion and malignant celiac effusion is a severe complication of the advanced malignant tumor, The formation of malignant pleural effusion and malignant celiac effusion relied on VEGF growth factor.Apatinib blocking vascular endothelial growth factor (VEGF) combining with the receptor and blocking signal transduction pathway, thereby inhibiting tumor and the formation of new blood vessels, inhibit the formation of the malignant pleural effusion and malignant celiac effusion. We conducted the study to exploring the single-agent oral path of Apatinib for the treatment of malignant pleural effusion and malignant celiac effusion of the clinical curative effect. Methods: Patients were eligible for inclusion in the study if they had histologically confirmed malignancies, with malignant pleural effusion and malignant celiac effusion. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Study Objective: Clinical curative effect. Study Design and Treatment: This study recruited 13 patients with histologically confirmed malignancies, and the patients with malignant pleural effusion and malignant celiac effusion from January 2016 to October 2016. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. All patients were given the oral drug Apatinib, the doses of oral given is 500 mg or 425 mg everyday until progressive disease (PD) or intolerable toxicity. Assessment and Statistical analysis: The assessmet were determined according to the World Health Organization (WHO) criteria. The ORR and DCR analyses were based on frequencies. Results:Table381P Baseline patient characteristicsCharacteristic Apatinib(n = 13)Age(years)Median(range) 58(44-84) Sex Male 7(53.85) Female 6(46.15) EGOG PS 0 2(15.38) 1 6(46.15) 2 5(38.46) Carcinoma Lung cancer 6(46.15) Pancreatic cancer 4(30.77) Breast cancer 2(15.38) Thymic cancer 1(7.7)Efficacy: Apatinib is effective for the treatment of malignant pleural effusion and malignant celiac effusion: CR 5 cases, PR 5 cases, SD 3 cases, overall-response rate (ORR)76.92%, disease-control rate (DCR)100%. Open table in a new tab Efficacy: Apatinib is effective for the treatment of malignant pleural effusion and malignant celiac effusion: CR 5 cases, PR 5 cases, SD 3 cases, overall-response rate (ORR)76.92%, disease-control rate (DCR)100%. Conclusions: Apatinib is a safe, feasible way in the treatment of malignant pleural effusion and malignant celiac effusion. Relying on the simple method and favourable rencent curative effect. Apatinib provides a new way for the treatment of malignant pleural effusion and malignant celiac effusion that deserves further research. Legal entity responsible for the study: GuoXin Ma Funding: None Disclosure: All authors have declared no conflicts of interest.